4162 智擎 - 😊Conclusions: First-line NALI...

\ud83d\ude0aConclusions:

OX · 2023-01-21T16:12:32Z

\ud83d\ude0aConclusions: First-line NALIRIFOX demonstrated clinically meaningful and statistically significant improvement in OS and PFS compared with Gem+NabP in treatment-naïve patients with mPDAC. The safety profile of NALIRIFOX was manageable and consistent with the profiles of the treatment components. https://meetings.asco.org/abstracts-presentations/215522 https://www.onclive.com/view/frontline-liposomal-irinotecan-nalirifox-elicits-os-benefit-in-metastatic-pancreatic-ductal-adenocarcinoma https://vhio.net/2023/01/20/napoli-3-nalirifox-shows-promise-as-first-line-therapy-in-patients-with-metastatic-pancreatic-ductal-adenocarcinoma/